Impact of Genetic Polymorphisms And DASH Diet On Weight Loss Progression In Climacteric Women With Metabolic Syndrome

Launched by NUTRINDO IDEAIS RESEARCH CENTER · May 16, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how certain genetic factors and a specific diet called the DASH diet can affect weight loss in menopausal women who have metabolic syndrome. Metabolic syndrome is a collection of health issues that often includes obesity, high blood pressure, and diabetes. The trial aims to see if the DASH diet, which emphasizes fruits, vegetables, and whole grains, can help these women lose weight and improve their health, while also looking at how their genes might influence these changes.

To participate in this study, women must be between the ages of 40 and 60, be classified as obese (having a body mass index or BMI over 30), and have at least three specific health issues related to metabolic syndrome. For example, they might have a larger waist size, high blood pressure, or elevated blood sugar levels. Participants can expect to share some health information and undergo laboratory tests to track their progress throughout the study. It’s important to note that women with certain medical conditions, like active cancer or severe kidney disease, cannot join the trial, as these issues could affect the results.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • The study population will consist of menopausal women aged between 40 to 60 years old
• • Obese (BMI \> 30) with a diagnosis of MS.
• The inclusion criteria are the presence of at least 3 of the 5 criteria\* for MS, which include:
• • Abnormal waist circumference values (≥89 cm in women)
• • SBP ≥120 mm Hg and DBP ≥80 mm Hg) or diagnosis of hypertension
• • Fasting blood glucose equal to or greater than 100 mg/dL or diagnosis of DM2
• • HDL-c less than 50 mg/dL in women
• • Triglycerides ≥150 mg/dL.
• Exclusion Criteria:
• • Patients with a BMI \<25 kg/m2
• The following chronic diseases will not be eligible:
• • Active cancer
• • Active tuberculosis
• • Psychiatric illnesses
• • Multiple sclerosis
• • Severe nephropathy
• • Advanced stages of Paget's disease.
• • These chronic conditions could interfere with the results of this study, especially adherence to diet and weight loss. Patients who do not complete all stages of the study, who are not adhering to the intervention or who present any complication that interferes with the results of the study will be excluded from the study.